Single Cell RNA Sequencing Analysis of the Immune Microenvironment in Treatment Resistant Esophageal Squamous Cell Carcinoma
- Authors
-
-
Abhishek Kumar Gupta
Kalinga University, Naya Raipur, Chhattisgarh, India -
Anand Trivedi
Kalinga University, Naya Raipur, Chhattisgarh, India
-
- Keywords:
- Esophageal Squamous Cell Carcinoma (ESCC), Tumor Immune Microenvironment (TIME), Single-Cell RNA Sequencing (scRNA-seq), Treatment Resistance, Exhausted T Cells, Exhausted T CellsMetabolic Reprogramming
- Abstract
-
Esophageal squamous cell carcinoma (ESCC) is a very aggressive disease that does not respond to the traditional methods of treatment, including chemotherapy and immunotherapy, and therefore has a low prognosis. Tumor immune microenvironment (TIME) is an important factor that contributes to resistance because it affects the function of immune cells and their interactions with tumor cells. The cellular composition and functional state of the immune microenvironment of the treatment-resistant ESCC were examined in the work by means of single-cell RNA sequencing (scRNA-seq). The populations of immune cells were observed to differ in the event of treatment-resistant and treatment-responsive ESCC. There were more exhausted CD8 + T cells, regulatory T cells (Tregs), and immunosuppressive macrophages in the treatment-resistant group. These cells also had high levels of immune checkpoint markers like PD-1, PD-L1, and CTLA-4, which are identified to play a role in inhibiting effective immune responses. In addition, there was also a metabolic reprogramming of these immune populations with an increased glycolytic activity, which leads to a dysfunction of immune cells and allows tumors to survive. Using gene set enrichment analysis (GSEA), there were a few pathways that were upregulated in the resistant cohort, such as immune checkpoint signaling, inflammatory responses, and metabolism pathways. These observations support the assumption that immune escape and metabolic restructuring are two influential factors in ESCC resistance. The findings indicate that both immune checkpoints and the metabolic reprogramming of immune cells may be combined therapies to provide a promising approach in overcoming treatment resistance in ESCC. The findings need to be validated in future studies with larger patient groups, multi-omics studies, and clinical trials to come up with better treatment options among ESCC patients.
- Downloads
-
Download data is not yet available.
- References
-
[1] Yang Y, Li Y, Yu H, Ding Z, Chen L, Zeng X, et al. Comprehensive landscape of resistance mechanisms for neoadjuvant therapy in esophageal squamous cell carcinoma by single-cell transcriptomics. Signal Transduction and Targeted Therapy 2023; 8(1): 298.
[2] Shi K, Li Y, Yang L, Zhang Z, Guo D, Zhang J, Lu Y. Profiling transcriptional heterogeneity of epithelium, fibroblasts, and immune cells in esophageal squamous cell carcinoma by single‐cell RNA sequencing. The FASEB Journal 2022; 36(11): e22620.
[3] Guo W, Zhou B, Yang Z, Liu X, Huai Q, Guo L, et al. Integrating microarray-based spatial transcriptomics and single-cell RNA-sequencing reveals tissue architecture in esophageal squamous cell carcinoma. EBioMedicine 2022; 84.
[4] Liang J, Lei K, Liang R, Huang J, Tan B, Lin H, Wang M. Single-cell RNA sequencing reveals the MIF-ACKR3 receptor-ligand interaction between iCAFs and tumor cells in esophageal squamous cell carcinoma. Cellular Signalling 2024; 117: 111093.
[5] Zhang X, Peng L, Luo Y, Zhang S, Pu Y, Chen Y, et al. Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis. Nature Communications 2021; 12(1): 5291.
[6] Liu J, Chen H, Qiao G, Zhang JT, Zhang S, Zhu C, et al. PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma. Cancer Immunology, Immunotherapy 2023; 72(4): 881-893.
[7] Wen J, Fang S, Hu Y, Xi M, Weng Z, Pan C, et al. Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma. EBioMedicine 2022; 86.
[8] Li R, Huang B, Tian H, Sun Z. Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment. Frontiers in Oncology 2023; 12: 1096717.
[9] Zhou B, Guo W, Guo L, Li Y, Zheng Z, Huai Q, et al. Single-cell RNA-sequencing data reveals the genetic source of extracellular vesicles in esophageal squamous cell carcinoma. Pharmacological Research 2023; 192: 106800.
[10] Yang Z, Tian H, Chen X, Li B, Bai G, Cai Q, et al. Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma. Nature Communications 2024; 15(1): 9097.
[11] Huang Z, Cong Z, Luo J, Qiu B, Wang K, Gao C, et al. Association between cancer-associated fibroblasts and prognosis of neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma: a bioinformatics analysis based on single-cell RNA sequencing. Cancer Cell International 2025; 25(1): 74.
[12] Li Q, Xu S, Ren Y, Zhang C, Li K, Liu Y. Single-cell RNA sequencing reveals adrb1 as a sympathetic nerve-regulated immune checkpoint driving T cell exhaustion and impacting immunotherapy in esophageal squamous cell carcinoma. Frontiers in Immunology 2025; 16: 1520766.
[13] Chen Z, Zhao M, Liang J, Hu Z, Huang Y, Li M, et al. Dissecting the single-cell transcriptome network underlying esophagus non-malignant tissues and esophageal squamous cell carcinoma. EBioMedicine 2021; 69.
[14] Wang C, Xie G, Jia M, Xu L, Ruan R, Yu C, et al. Single-cell profiling identifies biomarkers for immunochemotherapy in esophageal squamous cell carcinoma. Cancer Letters 2025; 217988.
[15] Deng T, Wang H, Yang C, Zuo M, Ji Z, Bai M, et al. Single cell sequencing revealed the mechanism of PD-1 resistance affected by the expression profile of peripheral blood immune cells in ESCC. Frontiers in Immunology 2022; 13: 1004345.
[16] Guo W, Zhou B, Dou L, Guo L, Li Y, Qin J, et al. Single-cell RNA sequencing and spatial transcriptomics of esophageal squamous cell carcinoma with lymph node metastases. Experimental & Molecular Medicine 2025; 57(1): 59-71.
[17] Li C, Song W, Zhang J, Luo Y. Single-cell transcriptomics reveals heterogeneity in esophageal squamous epithelial cells and constructs models for predicting patient prognosis and immunotherapy. Frontiers in Immunology 2023; 14: 1322147.
[18] Oyoshi H, Du J, Sakai SA, Yamashita R, Okumura M, Motegi A, et al. Comprehensive single-cell analysis demonstrates radiotherapy-induced infiltration of macrophages expressing immunosuppressive genes into tumor in esophageal squamous cell carcinoma. Science Advances 2023; 9(50): eadh9069.
[19] Xu B, Tseng I, Zhang X, Chen H, Del Campo ER, Deng J, et al. Immune characteristics and genetic markers of esophageal cancer by single-cell analysis: implications for immunotherapy. Journal of Thoracic Disease 2023; 15(4): 1805.
[20] Barroux M, Househam J, Lakatos E, Ronel T, Baker AM, Salié H, et al. Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of esophageal adenocarcinoma. Nature Cancer 2025; 6(5): 820-837.
- Downloads
- Published
- 09-06-2026
- Issue
- Vol. 15 No. 1 (2026)
- Section
- Articles
- License
-

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Similar Articles
- Chiranjeev Singh, Prachi Gurudiwan, Nanoparticle-Based Drug Delivery Systems for Tumor Treatment: Advancing Solutions to Overcome Drug Resistance , Journal of Cancer Research Updates: Vol. 14 (2025)
- Guanghui Yang, Honglu Zhang, Glenn D. Prestwich, Tissue-Engineered “Metastases”: Treatment of Hepatic Colon Tumors with a Dual Action Autotaxin Inhibitor-Lysophosphatidic Acid Receptor Antagonist , Journal of Cancer Research Updates: Vol. 1 No. 1 (2012)
- Sandip K. Mishra, K. Kanchan, Dharmendra K. Bhargava, A Review on EZH2 and its Epigenetic Association with Breast Cancer , Journal of Cancer Research Updates: Vol. 1 No. 2 (2012)
- Yao Li, Meng-Ning Wei, Wen-Ji Zhang, Zhi Shi, A HPLC-UV Method for the Quantification of Regorafenib in Tumor , Journal of Cancer Research Updates: Vol. 9 No. 1 (2020)
- Wenying Zhang, Hui Di, Renpei Xia, Jiali Yang, Junfeng Zhang, Jianyou Gu, PSMD14 Drives Clear Cell Renal Cell Carcinoma Progression via JAK/STAT3 Signaling , Journal of Cancer Research Updates: Vol. 15 No. 1 (2026)
- Abdulkareem Ahmed, Ahmed Nihad, Ghaeeb Sabreen, Youssef Shakuri Yasin, Jumaa Azal, Synergistic Antiproliferative Effect of Linagliptin-Metformin Combination on the Growth of Hela Cancer Cell Line , Journal of Cancer Research Updates: Vol. 14 (2025)
- Kang-Yao Zeng, Qing-Yi Zhou, Yun-Xi Zhang, Zhe-Sheng Chen, Zhi Shi, Song-Wang Cai, Apoptozole Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer , Journal of Cancer Research Updates: Vol. 14 (2025)
- Shahad Alqaraagholi, Dhafer A. Alghezi, Rasha Q. Aljawher, Immunohistochemical Evaluation of CD3+ and CD8+ tumour-Infiltrating Lymphocytes and their Association with Clinicopathological Features in Breast Cancer , Journal of Cancer Research Updates: Vol. 15 No. 1 (2026)
- Ana-Matea Mikecin, Mira Grdisa, TAT-Mediated Delivery of p27 in Tumor Cell Lines as a Potential Therapeutic Peptide , Journal of Cancer Research Updates: Vol. 1 No. 1 (2012)
- Kawakeb N. Abdulla, Rasha Kareem Khudhur, Ali Muafaq Said, Azal Hamoody Jumaa, Youssef Shakuri Yasin, Laetrile and Methotrexate: A Dual-Drug Approach to Inhibiting Cervical Cancer Cell Proliferation , Journal of Cancer Research Updates: Vol. 14 (2025)
You may also start an advanced similarity search for this article.
